about
An empirical approach to model selection through validation for censored survival data.The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.A hybrid approach to survival model building using integration of clinical and molecular information in censored data.The mortality risk of elevated serum transferrin saturation and consumption of dietary iron.HEART Pathway Accelerated Diagnostic Protocol Implementation: Prospective Pre-Post Interrupted Time Series Design and Methods.Prediction of morbidity and mortality in patients with type 2 diabetesPredicting 6-year mortality risk in patients with type 2 diabetes.Changes in Characteristics and Treatment Patterns of Patients with Newly Diagnosed Type 2 Diabetes in a Large United States Integrated Health System between 2008 and 2013Health care and productivity costs associated with diabetic patients with macrovascular comorbid conditions.Predicting patient discharge disposition after total joint arthroplasty in the United States.Antibiotics for the secondary prevention of ischemic heart disease: a meta-analysis of randomized controlled trials.Association of ferritin and lipids with C-reactive protein.Predicting organ space surgical site infection with a nomogram.Association between dietary arginine and C-reactive protein.The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.Statins and cancer: a meta-analysis of case-control studies.Are thyroid peroxidase antibodies associated with cardiovascular disease risk in patients with subclinical hypothyroidism?Iron, lipids, and risk of cancer in the Framingham Offspring cohort.Response to Comment on: Pantalone et al. The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy: A Retrospective Analysis. Diabetes Care 2010;33:1224–1229.Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system.Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients With Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated Health System.Nutritional markers may identify patients with greater risk of re-admission after geriatric hip fractures.Effect of glycemic control on the Diabetes Complications Severity Index score and development of complications in people with newly diagnosed type 2 diabetes.Predicting Current Glycated Hemoglobin Values in Adults: Development of an Algorithm From the Electronic Health RecordEnd-of-Life Issues and Spiritual HistoriesPredicting Current Glycated Hemoglobin Values in Adults: Development of an Algorithm From the Electronic Health Record (Preprint)Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysisThe risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysisDefining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysisAngiotensin-converting enzyme inhibitors reduce albuminuria more than angiotensin receptor blockers in patients with type 2 diabetesUse of Visual Decision Aids in Physician-Patient Communication: A Pilot InvestigationA Pain eHealth Platform for Engaging Obese, Older Adults with Chronic Low Back Pain in Nonpharmacological Pain Treatments: Protocol for a Pilot Feasibility Study
P50
Q33824720-9C0DEAED-57F2-433B-8FD3-18B2403ED257Q33873053-43D5332A-F4A2-454B-B91C-3B20BEE88DC7Q34164635-90CC6CEE-39FD-489A-90D8-9907988BD4D6Q34628387-A00CBE9B-91B0-445C-9A18-3FAC05A4D4D9Q36553030-C5E9E8FE-E97C-436E-81DE-C34B863AF9B2Q36936666-D38E649A-CECD-4D27-A900-DD49D53319EAQ36975679-927AAFC1-7E2E-4558-ABE6-ED060E8F60EAQ37058711-DC3D8E21-5861-46B9-BBA8-2D553F732429Q37437079-12F6FFF1-5990-4FB2-BBDD-480FF0A61E16Q37591638-BB75B8D1-A478-4178-B6D4-FA821BAB81C8Q37866212-DB0159A6-8614-4B35-80FB-68587D6E2F43Q40527997-89911F12-BA8B-4496-8760-27A2002E7BFEQ43275540-A8737965-24F1-447D-BA35-8194AFF562F1Q45276983-7794F0AD-B0A2-4930-B079-68FC760CEFEBQ46132812-B66EF8C7-2AED-4B8F-B5F5-994EB78F16E3Q46188631-5D844298-B864-4073-9D37-1E0903DE3AB1Q46457276-FF99618B-D44E-40F4-A606-F2A477A4502DQ46529063-347DB208-6C2D-43F6-AF4B-E15891175724Q46887711-9314BCE4-E8CF-4FF8-9DF7-F1990F5B673BQ47129129-6696BF9A-B58B-4E81-8505-96DA0AF5AE2CQ47406254-873EC306-A140-47CD-BD5E-991B8022BCDAQ49500861-47BAA453-CD0C-4319-9F12-9F1A3C551B28Q49613716-D60214B5-24B5-4C4B-B384-2AC14F644854Q57804324-0BB29F65-19C7-42AC-B5DF-EC6EC2126CF4Q61782772-933E63F2-5DE5-4E08-9D65-95FDEA2C4D93Q63966603-C9F445E1-5A68-488F-98BD-1381710B3E95Q63966646-403D9AA1-1ABA-41FD-88D1-E3224B5B5B05Q63966651-2B093162-CAB3-473C-B4AC-9C66041F30C5Q84911150-40B4E50F-9AD7-4BC8-A881-5A78A028C514Q86173266-D153B6BB-89B3-4587-86D1-6E43D7AEF790Q91441096-B8D984B6-9B39-42A3-BAFE-F4601F30633EQ92371338-A41BFA69-4040-4EFD-961B-3BC685B48A72
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Brian Wells
@ast
Brian Wells
@en
Brian Wells
@es
Brian Wells
@nl
Brian Wells
@sl
type
label
Brian Wells
@ast
Brian Wells
@en
Brian Wells
@es
Brian Wells
@nl
Brian Wells
@sl
prefLabel
Brian Wells
@ast
Brian Wells
@en
Brian Wells
@es
Brian Wells
@nl
Brian Wells
@sl
P106
P1153
7102754661
P21
P31
P496
0000-0001-7310-6525